Literature DB >> 11927523

Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis.

Anke Burger-Kentischer1, Heike Goebel, Rüdiger Seiler, Gustav Fraedrich, Hans E Schaefer, Stefanie Dimmeler, Robert Kleemann, Jürgen Bernhagen, Christian Ihling.   

Abstract

BACKGROUND: Atherosclerosis is a chronic inflammatory response of the arterial wall to injury. Macrophage migration inhibitory factor (MIF), a cytokine with potent inflammatory functions, was thus considered to be important in atherosclerotic lesion evolution. METHODS AND
RESULTS: We studied the presence and distribution of MIF immunoreactivity (MIF-IR) and MIF mRNA in internal mammary arteries with a normal histology and arteries with plaques in different stages of human atherosclerosis. To address a potential role for the coactivator Jab1 as a cellular mediator of MIF effects in vascular tissue, we correlated the expression of MIF to that of Jab1 by using immunohistochemistry and coimmunoprecipitation. We further sought to determine a potential functional role for endothelium-derived MIF in early atherogenesis by studying the effects of oxidized LDL on MIF expression in cultured human umbilical vascular endothelial cells. The results showed that MIF-IR and Jab1-IR are found in all cell types present in atherosclerotic lesions, that MIF-IR is upregulated during progression of atherosclerosis, that MIF is produced locally in the arterial wall, and that all MIF(+) cells are simultaneously Jab1(+). Coimmunoprecipitation experiments demonstrated in vivo complex formation between MIF and Jab1 in plaques. MIF expression in human umbilical vascular endothelial cells and a macrophage line was upregulated after stimulation with oxidized LDL.
CONCLUSIONS: MIF is produced abundantly by various cells in all types of human atherosclerotic lesions and thus may play an important role in early plaque development and advanced complicated lesions. MIF-Jab1 complexes could serve critical regulatory functions in atherosclerotic lesion evolution.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927523     DOI: 10.1161/01.cir.0000012942.49244.82

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  78 in total

Review 1.  D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family.

Authors:  Melanie Merk; Robert A Mitchell; Stefan Endres; Richard Bucala
Journal:  Cytokine       Date:  2012-04-14       Impact factor: 3.861

2.  Serum macrophage migration inhibitory factor is correlated with atrial fibrillation.

Authors:  Chunfu Wan; Zhihua Li
Journal:  J Clin Lab Anal       Date:  2017-04-13       Impact factor: 2.352

3.  Comparative genome-wide transcriptional analysis of human left and right internal mammary arteries.

Authors:  Giovanni Ferrari; John Quackenbush; John Strobeck; Lan Hu; Christopher K Johnson; Andrew Mak; Richard E Shaw; Kathleen Sayles; Mariano E Brizzio; Alex Zapolanski; Juan B Grau
Journal:  Genomics       Date:  2014-05-20       Impact factor: 5.736

4.  Macrophage Migration Inhibitory Factor Levels Correlate with Stroke Recurrence in Patients with Ischemic Stroke.

Authors:  Guangjie Wang; Chuanbin Li; Yashou Liu; Lei Xia
Journal:  Neurotox Res       Date:  2018-12-01       Impact factor: 3.911

5.  Immunosuppressive treatment protects against angiotensin II-induced renal damage.

Authors:  Dominik N Muller; Erdenechimeg Shagdarsuren; Joon-Keun Park; Ralf Dechend; Eero Mervaala; Franziska Hampich; Anette Fiebeler; Xinsheng Ju; Piet Finckenberg; Jürgen Theuer; Christiane Viedt; Joerg Kreuzer; Harald Heidecke; Hermann Haller; Martin Zenke; Friedrich C Luft
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

Review 6.  MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics.

Authors:  Pathricia V Tilstam; Dake Qi; Lin Leng; Lawrence Young; Richard Bucala
Journal:  Expert Opin Ther Targets       Date:  2017-07       Impact factor: 6.902

7.  Mif-deficiency favors an atheroprotective autoantibody phenotype in atherosclerosis.

Authors:  Corinna Schmitz; Heidi Noels; Omar El Bounkari; Eva Straussfeld; Remco T A Megens; Marieke Sternkopf; Setareh Alampour-Rajabi; Christine Krammer; Pathricia V Tilstam; Norbert Gerdes; Christina Bürger; Aphrodite Kapurniotu; Richard Bucala; Joachim Jankowski; Christian Weber; Jürgen Bernhagen
Journal:  FASEB J       Date:  2018-03-15       Impact factor: 5.191

8.  Direct modification of the proinflammatory cytokine macrophage migration inhibitory factor by dietary isothiocyanates.

Authors:  Kristin K Brown; Frances H Blaikie; Robin A J Smith; Joel D A Tyndall; Hongqi Lue; Jürgen Bernhagen; Christine C Winterbourn; Mark B Hampton
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

Review 9.  Chemokine-like functions of MIF in atherosclerosis.

Authors:  Andreas Schober; Jürgen Bernhagen; Christian Weber
Journal:  J Mol Med (Berl)       Date:  2008-04-02       Impact factor: 4.599

10.  Differential and cell-type specific regulation of responses to Toll-like receptor agonists by ISO-1.

Authors:  Peter W West; Lisa C Parker; Jon R Ward; Ian Sabroe
Journal:  Immunology       Date:  2008-03-18       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.